The prepared FMT-SLNs-PS80 evaluated for their anti-Parkinson’s efficacy in rotenone models in mice showed a significant dose dependent reduction of rotenone induced changes in locomotor activity, muscle strength, and memory, and also levels of CAT, SOD and GSH. The gene discussed is SOD1; the disease is Parkinson disease.